Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation

Table 1 Patient characteristics and outcomes on stereotactic body radiotherapy for graft hepatocellular carcinoma recurrence after liver transplantation

No.	Sex	Age	Index recurrence					Distant recurrence	Systemic therapy	Regional therapy	SBRT (dose/fraction)	Best local response	Disease progression	Time to progression (mo)	Follow up time		Toxicity/Grade
			Time after transplant (mo)	First	No.	Size (cm)	Location								From first recurrence (mo)	From SBRT (mo)
				Recurrence
1	M	36	58.2	No	1	2.4	S7	No	SRL	No	50 Gy/5	CR	Regional/distant	6.5	132	84.2	Dyspepsia/1
		37	66.5	No	1	1.9	S6	Lung	SRL/SECOX	No	50 Gy/5	CR	Distant	10.9
2	M	66	69.4	Yes	2	3.6	S8	No	EVL	No	45 Gy/5	PR	Regional	9.5	31.3	28
						3.1	S7/IVC thrombus
		66	81.8	No	2	2	S8	No	EVL	No	40 Gy/5	SD	Regional	3.3
						0.7	S7
		67	86.7	No	1	1.2	S6	No	EVL	No	40 Gy/5	SD	Regional	3.2
3	M	60	12.5	Yes	2	3.3	S7/IVC thrombus	No	EVL/Sorafenib	No	37.5 Gy/5	CR	Regional	10.3	19	15.5	Dyspepsia/1
						2.3	S6
4	M	63	24.5	Yes	1	2.8	S3	No	EVL	No	37.5 Gy/5	SD	Regional	3.3	9	6.4	Gastric ulcer/2
5	M	57	1.2	Yes	1	1	Portal LN	No	EVL/Lenvatinib	No	45 Gy/5	CR	No	-	6.9	6.3
6	M	58	75.8	No	1	2.5	S5	No	EVL	TACE	50 Gy/5	CR	No	-	30.8	1.8	Diarrhoea/1

CR: Complete response; EVL: Everolimus; IVC: Inferior vena cava; LN: Lymph node, PR: Partial response; SD: Stable disease; SRL: Sirolimus; TACE: Trans-arterial chemoembolization.

Table 2 Summary of patient, liver function, tumour and treatment characteristics

	Range (%)
Age	59 (31-66)
Gender (male), n (%)	6 (100)
Type of graft
Whole	4 (67)
Right lobe	2 (33)
Within UCSF, n (%)	4 (67)
Time to first recurrence (mo)	18.5 (1.2-69.4)
Time to index recurrence (mo)	66.5 (1.2-86.7)
ECOG	1 (0-1)
Bilirubin (umol/L)	9 (4-23)
Albumin (g/L)	43 (39-47)
ALT (U/L)	28 (19-44)
AST (U/L)	33 (18-58)
INR	1.0 (1.0-1.5)1
Platelet (× 109/L)	124 (43-255)
Creatinine (umol/L)	107 (78-121)
Index lesion as first recurrence, n (%)	4 (44)
Number of index lesions	1 (1-2)
Tumour size (cm)	2.3 (0.7-3.6)
IVC invasion, n (%)	2 (22)
Distant recurrence, n (%)	1 (11)
AFP (ng/mL)	4 (2-1354)
Prescribed dose (Gy)	45 (37.5-50)
Number of fractions	5 (5-6)
Dose per fraction (Gy)	8 (7.5-10)
Treatment duration (d)	5 (5-14)
Concomitant sysetmic treatment, n (%)	6 (100)

¹One patient on warfarin had INR ≥ 1.5. ECOG: Eastern Cooperative Oncology Group; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate aminotransferase; AFP: Alpha-fetoprotein; USCF: University of California San Francisco; IVC: Inferior vena cava.